NCT04472832View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo for Treatment A

6 tablets matched to mitapivat tablet

DRUG

Mitapivat 100 mg

Two 50-mg tablets

DRUG

Placebo for Treatment B

4 tablets matched to mitapivat tablet

DRUG

Mitapivat 300 mg

Six 50-mg tablets

DRUG

Placebo for Treatment C

4 tablets matched to mitapivat tablet

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY